Go to Contents Go to Navigation

Samsung Bioepis inks commercialization agreement with Biogen

Welfare/Medicine 10:48 November 07, 2019

By Kim Han-joo

SEOUL, Nov. 7 (Yonhap) -- South Korean pharmaceutical firm Samsung Bioepis Co. said Thursday it has entered into a new commercialization agreement worth US$370 million with U.S. partner Biogen.

Under the partnership, Biogen will be responsible of marketing and sales of Samsung Bioepis' two biosimilars -- SB11 and SB15 -- and two other ophthalmology biosimilars that are currently in development.

The agreement also gives Biogen the option to extend its existing 10-year commercialization agreement for three anti-TNF biosimilars in Europe by five years.

"By building on this collaboration, we are excited to potentially expand the opportunity for patients living with ophthalmological conditions, who do not have access to life-changing medicines," Samsung Bioepis CEO Christopher Hansung Ko said in a press release.

Samsung Bioepis, established in 2012, currently has biosimilars approved and marketed across Europe and the U.S. -- Benepali, Imraldi, Ontruzant and Flixabi.

This undated photo provided by South Korean pharmaceutical firm Samsung Bioepis Co. shows its headquarters. (PHOTO NOT FOR SALE) (Yonhap)


Send Feedback
How can we improve?
Thanks for your feedback!